5PSQ-108 Abstract withdrawn

View at publisher Summarise with VIRAT
Authors: Cristina Portero Ponce, A Sánchez Blaya, María Guillén Díaz, A Martínez Orea, Estefanía Palazón Gonzálvez, R Alergía Samper, B Cabezuela Baldueza, C Gea Muñoz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Importance In May 2025, following the introduction by the Pharmacy Department (PD) of the new prefilled syringe formulations of faricimab 120 mg/mL and aflibercept 114.3 mg/mL, a joint consensus was developed with the Ophthalmology Department (OD) to establish an agreement on the therapeutic positioning of intravitreal therapies. During the pharmaceutical validation process, the PD verifies the indication of the prescribed drug and the dosing interval. When any error is detected, an incident report form is completed, indicating the patient’s appointment date, medical record number, and the problem identified. This report is sent to the OD, which subsequently informs the PD whether the proposed intervention is accepted or rejected. Aim and Objectives The purpose of this study is to describe the incidents detected during the validation of intravitreal therapies following the implementation of the PD–OD consensus, as well as to analyse the types of interventions performed and the acceptance rate by the OD. Material and Methods A descriptive, observational, and retrospective study was conducted between June and September 2025. An Excel database was used to record the type of incident, the intervention proposed by the PD, and whether it was accepted or rejected by the OD. Results A total of 38 incidents were detected during the pharmaceutical validation process, related either to the dosing interval or to the prescription of a drug without indication for the target pathology. Of these, 45% were due to incorrect dosing intervals and 55% to inappropriate drug indication. The interventions derived from these incidents consisted of extending the dosing interval or substituting the drug, in accordance with the established consensus. All interventions proposed by the PD were accepted by the OD (100%). Conclusion and Relevance The implementation of a PD–OD consensus has enabled the standardisation of intravitreal therapy use, facilitating the detection, communication, and correction of incidents during pharmaceutical validation. All interventions were accepted by the OD, demonstrating an improvement in the safety of intravitreal pharmacotherapy for patients. Conflict of Interest No conflict of interest

Fields of Study & Subjects

Pharmacy and Medical Practices Patient Safety and Medication Errors Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
European Journal of Hospital Pharmacy
Pages
A262.2–A262
Publication date
1 March 2026
Language
EN